The antidepressant fluoxetine protects the hippocampus from brain damage in experimental pneumococcal meningitis

F D Liechti1, D Grandgirard1, S L Leib2

  • 1Neuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, CH-3010 Bern, Switzerland.

Neuroscience
|April 4, 2015
PubMed
Abstract

Insights

Fluoxetine (FLX) demonstrates neuroprotective effects in infant rats with pneumococcal meningitis, reducing hippocampal apoptosis. This selective serotonin reuptake inhibitor (SSRI) shows promise as an adjuvant therapy for bacterial meningitis.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Infectious Diseases

Background:

  • Bacterial meningitis (BM) presents high mortality and morbidity, necessitating novel adjuvant treatments.
  • Hippocampal apoptosis and cortical ischemic necrosis are key pathological features of BM.
  • Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine (FLX) have demonstrated neuroprotective properties.

Purpose of the Study:

  • To evaluate the neuroprotective potential of fluoxetine (FLX) in an experimental model of pneumococcal meningitis.
  • To assess the impact of FLX on brain damage, specifically hippocampal apoptosis and cortical necrosis, in infant rats.

Main Methods:

  • Infant rats were infected with Streptococcus pneumoniae and treated with FLX or saline.
  • Clinical outcomes, inflammatory markers in cerebrospinal fluid (CSF), and brain histomorphology were assessed at multiple time points.
  • Apoptosis in the hippocampus and damage in cortical areas were quantified.

Main Results:

  • FLX treatment significantly reduced hippocampal apoptosis compared to controls (9/19 vs 18/23, P=0.038).
  • A trend towards reduced cortical damage was observed in FLX-treated rats, though not statistically significant.
  • FLX did not significantly alter clinical or inflammatory parameters in the CSF.

Conclusions:

  • Fluoxetine exhibits a significant neuroprotective effect on the hippocampus in experimental pneumococcal meningitis.
  • FLX may serve as a potential adjuvant therapy to mitigate specific brain injuries associated with bacterial meningitis.